Cerebral Compliance Impairment in COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04429477|
Recruitment Status : Completed
First Posted : June 12, 2020
Last Update Posted : September 22, 2020
|Condition or disease||Intervention/treatment|
|Intracranial Hypertension Cerebral Circulatory Failure||Device: Cerebral compliance and hemodynamics monitoring|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||50 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Assessment of Cerebral Compliance and Hemodynamics in Severe COVID-19|
|Actual Study Start Date :||May 1, 2020|
|Actual Primary Completion Date :||July 15, 2020|
|Actual Study Completion Date :||July 31, 2020|
- Device: Cerebral compliance and hemodynamics monitoring
Noninvasive devices are been used to assess cerebral circulation and compliance.
- Detection of cerebral compliance impairment by the B4C sensor [ Time Frame: During critical care, around 15 days/patient ]Observe alteration in cerebral compliance due to potential intracranial hypertension during severe COVID-19. This situation is indicated when the relation P2/P1 given by the B4C sensor is >1.
- Detection of cerebral hemodynamics impairment by transcranial Doppler [ Time Frame: During critical care, around 15 days/patient ]Observe disturbances in cerebral circulation during severe COVID-19, given by blood flow velocities in middle cerebral arteries (with normal range 40-70 cm/s) and the pulsatility index (normal <1.2) calculated by transcranial Doppler.
- Calculate mortality in this population [ Time Frame: 3 months ]Observe whether disturbances in cerebral compliance and hemodynamics assessed in this population is significantly associated with higher mortality.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04429477
|Hospital das Clínicas da Faculdade de Medicina da USP.|
|São Paulo, Brazil, 05403000|